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ABSTRACT
OBjECTIVE: Metformin treatment may induce a decrease/suppression in serum TSH levels, 
mimicking sub-clinical hyperthyroidism (SHT). The aim of the present study was to retro-
spectively evaluate changes in several electrocardiographic indices in euthyroid subjects with 
diabetes who, after starting metformin treatment, developed a low serum TSH as compared to 
patients with SHT resulting from an underlying thyroid disease or TSH suppressive treatment 
with L-thyroxine. DEsIGn: Heart rate, P wave duration, P wave dispersion, Qtmax, Qtmin 
and Qt-dispersion were assessed in 23 patients with diabetes treated with metformin before 
and after 6 months of tsH-suppression and in 31 control patients with sHt. REsuLts: 
No significant changes in electrocardiographic parameters were observed from baseline to 
the TSH-suppression measurement. A significant difference in P wave duration (102.9±7.4 
vs. 92.1±5.8 ms, p<0.001), P wave dispersion (13.1±3.4 vs. 7.1±3.5 ms, p<0.001), Qtmax 
(399±18 vs. 388±16 ms, p=0.024), Qtmin (341±14 vs. 350±17 ms, p=0.038) and Qt disper-
sion (49.9±9.6 vs. 30.9±9.2 ms, p<0.001) were observed between the control group with SHT 
and the group of diabetic patients with low serum levels of tsH. COnCLusIOns: Our results 
show that the TSH-suppressive effect observed in patients taking metformin is not associated 
with peripheral markers of thyroid hormone excess, at least at the cardiac level.
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INTRODUCTION
Metformin is a widely used drug for the treatment 
of patients with type 2 diabetes mellitus, but also 
in insulin resistance syndromes.1-3 It is commonly 
regarded as a safe drug in that no clinically relevant 
pharmacologic interactions have been described 
when it is prescribed in combination with the other 
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commonly used drugs, with the exception of folate 
and B12.4,5
Recent data from the literature, including those 
from our groups, indicate that metformin influences 
serum levels of thyroid-stimulating hormone (TSH) 
by decreasing serum concentration of pituitary hor-
mones both in hypothyroid patients treated with 
levothyroxine6,7 and in patients with diabetes with 
primary untreated hypothyroidism.8 Recently, a de-
crease of serum TSH was also observed in hypothyroid 
women being treated with metformin for an associated 
polycystic ovarian syndrome.9,10 This TSH-lowering 
effect of metformin has been extensively reported 
and, although the underlying mechanisms are not 
yet clear, several hypotheses have been addressed 
and well summarized in a recent review by Pappa 
and Alevizaki.11 However, the clinical significance 
of the low serum TSH remains yet to be clarified. 
Subclinical hyperthyroidism (SHT), characterized by 
low serum TSH and normal free thyroxine (fT4) and 
triiodothyronine (fT3) levels, may be due to either 
exogenous or endogenous causes. Although commonly 
asymptomatic, SHT is associated with an increased 
risk of cardiac arrhythmias, mostly atrial fibrillation, 
morphological and functional cardiac alterations,12,13 
resulting in increased cardiovascular morbidity and 
mortality.14-16 It was also shown that patients with 
SHT suffer from a sympathetic-vagal imbalance, 
characterized by an increased sympathetic activity 
in the presence of a diminished vagal tone,12,13,17 and 
may also display a prolonged QT interval.18
The aim of the present study was to retrospec-
tively evaluate the heart rate variability in euthyroid 
subjects with diabetes who, after starting metformin 
treatment, developed a low serum TSH. Their elec-
trocardiographic parameters were compared with 
those observed in patients with SHT resulting from 
an underlying thyroid disease or TSH suppressive 
treatment with L-thyroxine. In particular, P wave 
duration (Pmax), P wave dispersion (PWD) and 
QT dispersion were measured. The cardiac evalua-
tion was performed at baseline (i.e. before starting 
metformin treatment, when TSH was in the normal 
range) and at least 6 months after the development 
of a blunted serum TSH level. Our final goal was to 
clarify whether or not the metformin-induced reduc-
tion of serum TSH has electrocardiographic changes 
which, being similar to what is observed in real SHT, 
might warrant specific intervention.
SUBjECTS AND METHODS
Patients were recruited by searching the comput-
erized database of patients followed at the Diabetic 
Unit of Department of Medical and Surgical Sciences, 
University of Brescia, Italy. Search criteria included 
the availability of: 1) a complete medical history; 2) a 
detailed drug treatment schedule including any change 
during the study period; 3) a full thyroid hormone 
profile. We excluded patients with diabetes in whom 
the low metformin-induced serum TSH level was ob-
served for less than 6 months after initiation of treat-
ment with metformin. Patients with cardiovascular 
illnesses, including hypertension, even if treated, with 
cardiovascular autonomic dysfunction and smokers 
were also excluded. None of the patients enrolled 
in the study was taking ß-blockers, anti-arrhythmic 
drugs or anticholinergic drugs.
Among a total of 7020 patients with diabetes, 23 
subjects (18 females and 5 males; mean age 54±7 
years), who developed a low serum TSH (<0.4 mU/L) 
after starting metformin treatment, satisfied the in-
clusion and exclusion criteria. Serum tests for TSH, 
fT4 and fT3 were available at baseline (i.e. before 
metformin treatment) and repeated every 6 months. 
The control group included 31 patients (23 females 
and 8 males; mean age 52.9±8.1 years) with SHT 
who also satisfied the above described inclusion and 
exclusion criteria and had, at the time of evaluation, 
a low serum TSH lasting for at least 6 months. SHT 
was due either to a hyperfunctioning thyroid nodule 
(n=17) or to L-thyroxine TSH suppressive treatment 
for thyroid cancer (n=14).
Cardiovascular assessment
Electrocardiography (ECG) was performed at 
0.025 (25 mm/sec) in the supine position. Patients 
were allowed to breathe normally during ECG. The 
P wave duration was measured manually: the starting 
point of the P wave was taken at the junction of the 
deflection of the P wave from the iso-electric line. The 
end point of the P wave was taken at the junction of 
the end of the P wave and the iso-electric line. The 
Pmax and the minimum P duration were measured 
on ECG recordings. The P wave dispersion was calcu-
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lated as a Pmax-minumum P duration.19 QT intervals 
were measured manually in all the 12 leads from the 
onset of the QRS complex to the end of the T wave. 
Three consecutive QT intervals were measured and 
averaged for each lead. A minimum of nine leads in 
which the QT interval could be measured was required 
for QT dispersion to be determined. QT dispersion 
was defined as the difference between the longest and 
shortest QT interval. A skilled electrocardiography 
physician, blinded as to the patient’s clinical status, 
reviewed all the electrocardiograms.
Thyroid function tests
Serum concentrations of fT4 (normal range: 8.0-
19.0 pg/mL, analytical sensitivity 1 pg/mL; intra- and 
inter-assay coefficient of variation, 2.4% and 6.8%, 
respectively), fT3 (normal range: 2.4-4.7; analytical 
sensitivity 0.35 pg/mL; intra- and inter-assay coefficient 
of variation, 4.6% and 6.5%, respectively), and TSH 
(normal range: 0.4-4.5 mIU/L, analytical sensitivity 
0.004 mlU/L; intra- and inter-assay coefficient of varia-
tion, 2.5% and 5.7%, respectively) were measured using 
immunochemiluminescent assays by an automated 
analyzer (Immulite 2000, DPC Cirrus, Los Angeles, 
CA, USA) employing commercial kits (Diagnostic 
Products Corporation, Los Angeles, CA, USA).
Statistical analysis
Statistical analysis was performed using SPSS 
software (SPSS, Inc., Evanston, IL). Longitudinal 
measures were compared by ANOVA or by the Wil-
coxon test according to a normal or a nonparametric 
distribution of the tested variable. Between groups 
comparisons were performed by Student’s t-test for 
unpaired data or by the Mann-Whitney U-test accord-
ing to a normal or a nonparametric distribution of 
the tested variable. Correlation between two variables 
was ascertained by Pearson or Spearman’s correla-
tion tests, as appropriate. Frequencies among groups 
were compared by the χ2 test with Fisher’s correction, 
when appropriate. A p-value <0.05 was considered 
statistically significant. Data are expressed as mean 
± standard deviation (sd), unless otherwise stated.
RESULTS
The clinical and biochemical features of the 23 
patients with diabetes at baseline (i.e. before met-
formin treatment) and at least 6 months after the 
development of a low serum TSH (i.e. after initiation 
of treatment with metformin) are summarized in 
Table 1. A significant improvement of glycated hae-
moglobin was observed during the investigation period 
[7.3% (56 mmol/mol) ±0.9 vs 6.8% (51 mmol/mol) 
±0.6, p<0.05], whereas a slight but non-significant 
reduction of body mass index (BMI) was found when 
data before and after metformin were compared 
(27.4±0.9 vs 26.9±1.1 Kg/m2). No significant change 
was observed for the serum levels of fT4 and fT3. 
More importantly, no significant change in heart 
rate (76.3±6.1 vs 73.9±7 bpm), systolic (131.8±8.4 vs 
129.3±4.6 mmHg) and diastolic (83.4±9.3 to 81.2±8.7 
mmHg) blood pressure was observed.
Data regarding P wave dispersion and measure-
ments of the QT interval are displayed in Table 2. 
When the results obtained at baseline and after at 
least 6 months of low serum TSH were compared, 
no significant change was observed in the P wave 
duration (91.4±6.9 vs 92.1±5.8 ms), P wave disper-
sion (7.4±3.7 vs 7.1±3.5 ms), QTmax (390±17 vs 
388±16 ms), QTmin (348±18 vs 350±17 ms) and 
QT dispersion (30.8±9.1 to 30.9±9.2 ms).
To further evaluate this finding, patients with dia-
betes who developed a low serum TSH while treated 
with metformin were compared with control patients 
Table 1. Clinical and biochemical features of patients with diabetes 
at baseline (i.e. before metformin treatment) and at least 6 months 
after the development of a low serum TSH
Baseline,  
before metformin  
treatment
After at least  
6 months of low  
serum TSH
p value
BMI (Kg/m2) 27.4±0.9 26.9±1.1 NS
Heart Rate 
(bpm)
76.3±6.1 73.9±7.0 NS
Systolic Blood 
Pressure 
(mmHb)
131.8±8.4 129.3±4.6 NS
Diastolic 
Heart Pressure 
(mmHb)
83.4±9.3 81.2±8.7 NS
HbA1c (%) 7.3±0.9 6.8±0.6 <0.05
TSH (mIU/L) 1.1±0.7 0.1±0.2 <0.001
fT4 (pg/mL) 12.4±1.7 12.6±1.4 NS
fT3 (pg/mL) 2.9±0.6 3.0±0.8 NS
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having SHT. As shown in Table 3, the two groups 
displayed similar clinical and biochemical parameters. 
In particular, no difference was found for circulating 
thyroid function parameters, alcohol consumption, 
blood pressure and for heart rate. In addition, the 
mean period of low serum TSH was super-imposable 
between patients with diabetes and control group 
with SHT (1.0±0.7 vs 1.1±0.8 years, respectively). 
However, when the electrocardiographic measures 
were compared between the two groups, significant 
differences were observed. As shown in Figure 1, P 
wave duration (102.9±7.4 vs. 92.1±5.8 ms, p<0.001), 
P wave dispersion (13.1±3.4 vs. 7.1±3.5 ms, p<0.001), 
QTmax (399±18 vs. 388±16 ms, p=0.024), QTmin 
(341±14 vs. 350±17 ms, p=0.038) and QT dispersion 
(49.9±9.6 vs. 30.9±9.2 ms, p<0.001) were significantly 
different in subjects with SHT as compared to patients 
with diabetes having a low serum TSH while treated 
with metformin.
DISCUSSION
This study demonstrates that the blunted serum 
TSH induced by metformin treatment is not associ-
ated with changes of electrocardiographic parameters 
found in patients with real SHT. Indeed, significant 
differences were found when comparing Pmax, PWD, 
QTmax, QTmin and QT dispersion between patients 
with diabetes developing a low serum TSH while 
treated with metformin and patients with real SHT.
Since the first report by Vigersky R et al6 showing 
that metformin was able to decrease serum TSH levels 
in patients with diabetes and hypothyroidism, other 
studies confirmed this observation.6,8 In contrast, a 
recent analysis by Díez and Iglesias of a large cohort 
of patients with diabetes showed no independent 
and significant relationship between TSH values 
and metformin treatment in euthyroid patients with 
diabetes.20 Unfortunately, no data about TSH serum 
levels before metformin treatment were given; it is thus 
possible that the TSH levels of patients on metformin 
could be higher before its introduction. Recently, we 
have elaborated on this including euthyroid patients 
with diabetes and borderline high serum TSH levels 
(>2.5 mU/L) independently of the presence of thy-
roid antibodies.21
A major question regarding the metformin-induced 
reduction of serum TSH is whether or not this condi-
tion can be considered equivalent to SHT. As in fact 
suggested by Alevizaki, metformin could prove to be 
a very efficacious tool to induce TSH suppression 
without iatrogenic hyperthyroidism effects in thyroid 
cancer patients.22 Indeed, SHT is defined as a condi-
tion of lower than normal serum TSH associated with 
fT4 and fT3 in the normal range.23 SHT, which may 
result from endogenous thyroid diseases or exog-
enous factors, such as L-thyroxine treatment at TSH 
suppressive doses, is associated with corresponding 
alterations of the cardiovascular system, including 
Table 3. Clinical and biochemical features of patients with diabetes 
with TSH suppression and subjects with subclinical hyperthyroidism
Diabetics with  
low serum  
TSH while  
treated with  
metformin (23)
Control  
patients  
with SHT  
(31)
p 
value
Age (years) 54.7±9.8 52.9±8.1 NS
BMI (Kg/m2) 26.9±1.1 27.5±0.5 NS
Alcohol intake 
(2/3 glasses of 
wine daily) (n)
2/23 3/31 NS
Heart Rate (bpm) 73.9±7.0 80.3±4.1 NS
Systolic Blood 
Pressure (mmHb)
129.3±4.6 133.7±4.4 NS
Diastolic Blood 
Pressure (mmHb)
81.2±8.7 83.4±6.3 NS
TSH (mIU/L) 0.1±0.2 0.1±0.2 NS
fT4 (pg/mL) 12.6±1.4 12.8±0.7 NS
fT3 (pg/mL) 3.0±0.8 3.1±0.6 NS
Table 2. Heart rate variability of patients with diabetes at baseline 
(i.e. before metformin treatment) and at least 6 months after the 
development of a low serum TSH
Baseline, before 
metformin  
treatment
After at least  
6 months of low  
serum TSH
p
value
Pmax (ms) 91.4±6.9 92.1±5.8 NS
PWD (ms) 7.4±3.7 7.1±3.5 NS
QTmax (ms) 390±17 388±16 NS
QTmin (ms) 348±18 350±17 NS
Qt dispersion (ms) 30.8±9.1 30.9±9.2 NS
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morphological and functional cardiac alterations, 
and an increased risk of cardiac arrhythmias (mostly 
atrial fibrillation).23-29 A recent meta-analysis, which 
included more than 52,000 subjects, clearly indicated 
that SHT is also associated with increased risk of 
coronary heart events and mortality.14
Figure 1. Heart rate variability of patients with diabetes with low serum TSH and patients affected by subclinical hyperthyroidism.
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One of the earliest cardiovascular consequences 
of SHT is the occurrence of a sympathetic-vagal 
imbalance, characterized by increased sympathetic 
activity in the presence of a diminished vagal tone.12,13,17 
Owecki et al also showed that, in its early stages, 
SHT causes alterations of ventricular repolarization, 
represented by a prolonged QT interval.18 These 
electrocardiographic alterations are apparently due 
to the condition of mild hyperthyroidism, as assessed 
by the lower than normal serum TSH, rather than to 
an aetiology of thyrotoxicosis.8,30
The present study did not show alterations in 
sympathetic activity in patients with diabetes who ex-
perienced a metformin-induced, prolonged reduction 
of serum TSH to lower than normal levels. Indeed, 
Pmax, PWD, QTmax, QTmin and QT did not change 
throughout the study duration in patients with diabe-
tes. This was at variance with patients with real SHT, 
who displayed significantly increased measurements 
for these electrocardiographic parameters. The latter 
finding is in agreement with the recent literature.13,17
Taken together, our findings support the view that 
the reduction of serum TSH induced by metformin 
is not a manifestation of thyrotoxicosis but rather 
a “central” phenomenon involving a resetting of 
pituitary TSH secretion. This “effect” could have a 
practical clinical relevance. Indeed, TSH suppression 
could be achieved without the iatrogenic effects due 
to high doses of L-T4 normally used for this pur-
pose, reducing the risk of development of cardiac 
hypertrophy (increase of left ventricular mass index), 
diastolic dysfunction and arrhythmias (mostly atrial 
fibrillation),23 osteoporosis/osteoporotic fracture,31 
cognitive impairment32 and, moreover, of overall 
cause of mortality.33,34
Our interpretation is in line with the reported 
observation that the blunted TSH induced by met-
formin is not accompanied by clinical symptoms of 
hyperthyroidism6 or by any significant change of 
serum fT4 and fT3.
At the moment, the mechanisms by which met-
formin lowers serum TSH remain to be elucidated. As 
recently reviewed by Duntas, an emerging hypothesis 
to explain the TSH lowering effect of metformin 
involves the inhibition produced by this drug on hy-
pothalamic adenosine 5’-monophosphate-activated 
protein kinase (AMPK).35,36 Although few studies on 
the regulation of the hypothalamic isoforms (a1 and 
a2) of AMPK are available, the results provided by 
Lopez et al would support the concept that the action 
of metformin on AMPK activity could counteract the 
effects of T3 at the hypothalamic level.37 The result-
ing effects on TSH secretion are still incompletely 
understood. As a consequence, further studies are 
needed to fully explain the TSH lowering effect of 
metformin.
The small number of enrolled patients with dia-
betes, the relatively short period (6 months) of met-
formin-induced TSH suppression and the retrospective 
nature of the present study could represent a few 
limitations. However, the duration of TSH suppres-
sion was similar in control patients with endogenous 
or exogenous SHT.
In conclusion, our results suggest that the low 
serum TSH observed in patients taking metformin 
is not associated with signs of thyroid hormone ex-
cess at the cardiac level. As a consequence, if these 
data are confirmed in large prospective studies, this 
drug-induced biochemical condition will potentially 
no longer be viewed as indicative of SHT. Thus, the 
clinical message would be that there is no need to 
adjust the L-thyroxine dose in hypothyroid patients 
started on metformin, nor is there a need for strict 
thyroid biochemical surveillance of patients with 
diabetes taking metformin.
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